SN
Sonoma Pharmaceuticals, Inc.
SNOA · NASDAQ
$1.31 -2.61% (-$0.04)
1M +0.77%
Market Cap $2.21M
P/E Ratio -
Div. Yield -
ROE 53.56%
Bulios Fair Price
$1.46
11.9% upside
Current Price
$1.31
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SNOA is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
100 /100
Cheap P/B 0.33x
P/S 0.10x
P/FFO N/A
Growth
64 /100
Stable Book val. growth 27.06%
Rev. growth 13.74%
FCF growth N/A
Profitability
15 /100
Weak Net margin 10.33%
Op. margin 6.41%
FCF margin 9.82%
Quality
15 /100
Poor ROE 53.56%
ROA 12.50%
Asset turnover 1.21x
Debt
100 /100
Low Current ratio 2.99x
Debt/Equity 0.11x
Net debt/EBITDA N/A
Stability
59 /100
Moderate Rev. volatility 20.50%
EPS volatility 16.36%
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SNOA
Online
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Amy Trombly
Employees
10
Headquarters
Boulder
Upcoming events
16 NOV
Earnings
Upcoming earnings report